In Canada, a new prevention strategy called PrEP (pre-exposure prophylaxis) is being prescribed for high risk individuals, which calls for the daily use of HIV medication prior to infection.
However, PrEP is controversial because there are gaps in research regarding its prevention potential that may be affected by risk behaviour, sexual transmission, patient adherence to medication, and stigmatization. There are also concerns regarding equitable access because the majority of high risk HIV individuals also belong to marginalized communities. Dr. Darrell Tan is investigating these concerns by studying 1250 PrEP users in Ontario in a cohort study over 3 years. The results from this study will help inform future PrEP programs and improve PrEP accessibility in Canada.
CANFAR is partnering with the Ontario HIV Treatment Network (OHTN) and REACH 2.0 for this 3 year research partnership.